hydroxyproline and Osteitis Deformans studies

Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.
hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.

Osteitis Deformans: A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry.

Research Excerpts

Excerpt	Relevance	Reference
") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women."	7.69	Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994)
"Sixteen patients with painful Paget's disease of the bone were treated with high doses of ascorbic acid."	7.66	Ascorbic acid therapy for the relief of bone pain in Paget's disease. ( Basu, TK; Donaldson, D; Gillett, MB; Hicklin, JA; Jordan, SJ; Smethurst, M; Williams, DC, 1978)
"A significant correlation between the activity of the bone isoenzyme or serum alkaline phosphatase and the urinary hydroxyproline excretion in osteomalacia, osteoporosis, primary hyperparathyroidism with osteodystrophy, Paget's disease, secondary bone tumours, and in a control group was found (P less than 0."	7.66	Relationship of the activity of the bone isoenzyme of serum alkaline phosphatase to urinary hydroxyproline excretion in metabolic and neoplastic bone diseases. ( Formánková, J; Horn, V; Hrba, J; Konopásek, B; Marek, J; Pacovský, V; Silinková-Málková, E; Stĕpán, J; Vokrouhlická, O, 1978)
"Patient's with carcinoma metastases in bone and Pagent's disease of bone have different patterns of collagen metabolite excretion."	5.26	Urinary excretion of hydroxyproline, hydroxylysine and hydroxylysine glycosides by patients with Paget's disease of bone and carcinoma with metastases in bone. ( Kelleher, PC, 1979)
") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women."	3.69	Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994)
" An evaluation was made of deoxypyridinoline as well as other bone markets, such as alkaline phosphatase, tartrate resistant acid phosphatase, and hydroxyproline in patients with the diagnosis of osteoporosis."	3.69	[Deoxypyridinoline and other biochemical markers of bone resorption in distinct pathologies]. ( García Merlo, S; Grijalba Uche, A; Martínez Rodríguez, JL; Palacios Sarrasqueta, M; Rivero Marcotegui, A; Sorbet Zubiría, MJ, 1997)
"Twenty-one women with primary osteoporosis received an intramuscular injection of 100 IU of salmon calcitonin at 8 AM."	3.67	Acute antiosteoclastic effect of salmon calcitonin in osteoporotic women. ( Ghiringhelli, G; González, D; Mautalen, C, 1986)
"We have measured classic markers of bone turnover, serum alkaline phosphatase (sAP), urinary hydroxyproline/creatinine ratio (uOH-Prol/creatinine) and osteocalcin (sBGP), in two bone disorders characterized by an increase in bone remodelling, namely Paget's disease of bone and primary hyperparathyroidism (PHPT) and in two other bone diseases characterized by an increase in bone resorption without the concomitant increase in bone formation, hypercalcaemia of malignancy (HM) and involutional osteoporosis (IO)."	3.67	Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis. ( de la Piedra, C; Rapado, A; Torres, R, 1989)
"13 patients with polyosseous Paget's disease were treated for a mean period of 7 months with disodium etidronate (EHDP, ethylidene-1-hydroxy-1,1-diphosphonate); the average daily dosage was 5 mg/kg body weight."	3.67	[EHDP (ethylidene-1-hydroxy-1,1-diphosphonate) in the treatment of polyosseous Paget disease]. ( Frühwald, F; Kolbe, H; Kovarik, J; Niebauer, B; Woloszczuk, W, 1985)
"Free hydroxyproline was measured in plasma of 67 normal subjects and in 70 patients with bone disease including primary hyperparathyroidism (n = 19), osteoporosis (n = 18), Paget's disease (n = 14), cancer involving bone (n = 8), chronic renal failure (n = 6), and osteomalacia (n = 6), and osteomalacia (n = 5)."	3.67	Clinical significance of free plasma hydroxyproline measurement in metabolic bone disease. ( Antonelli, R; Mazzuoli, G; Minisola, S, 1985)
"Sixteen patients with painful Paget's disease of the bone were treated with high doses of ascorbic acid."	3.66	Ascorbic acid therapy for the relief of bone pain in Paget's disease. ( Basu, TK; Donaldson, D; Gillett, MB; Hicklin, JA; Jordan, SJ; Smethurst, M; Williams, DC, 1978)
"Serum proline iminopeptidase and (where possible) urinary hydroxyproline were determined in 214 subjects: normal subjects, subjects with chronic kidney disease, subjects with chronic liver disease, subjects with osteitis deformans, subjects with rheumatoid arthritis, and subjects with osteoporosis."	3.66	[Rarefying osteopathy in rheumatology. Methods of evaluation and comparison of urinary hydroxyproline and serum proline iminopeptidase]. ( Carrozzo, M; D'Amore, M; Martiradonna, A; Quarto, S; Terlizzi, N, 1980)
"A significant correlation between the activity of the bone isoenzyme or serum alkaline phosphatase and the urinary hydroxyproline excretion in osteomalacia, osteoporosis, primary hyperparathyroidism with osteodystrophy, Paget's disease, secondary bone tumours, and in a control group was found (P less than 0."	3.66	Relationship of the activity of the bone isoenzyme of serum alkaline phosphatase to urinary hydroxyproline excretion in metabolic and neoplastic bone diseases. ( Formánková, J; Horn, V; Hrba, J; Konopásek, B; Marek, J; Pacovský, V; Silinková-Málková, E; Stĕpán, J; Vokrouhlická, O, 1978)
"Hydroxyproline was measured in the plasma and urine of six patients with symptomatic osseous Paget's disease before and after parenteral mithramycin treatment."	3.65	Effect of mithramycin on hydroxyproline metabolism in Paget's disease. ( Ajlouni, K; Theil, GB, 1977)
"Alendronate was administered to 3 groups of 12 patients at doses of 2."	2.68	The effects of intravenous alendronate in Paget's disease of bone. ( Kanis, JA; Khan, S; McCloskey, EV; O'Doherty, DP; Vasikaran, S, 1995)
"Tiludronate at 400 mg/day for 3 months or 6 months is more effective than the same dosage of etidronate for 6 months in the treatment of Paget's disease."	2.68	Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. ( Devogelaer, JP; Dougados, M; Farrerons, J; Gennari, C; Kruse, HP; Mulder, H; Picot, C; Reginster, JY; Roux, C; Titeux, L, 1995)
"Gallium nitrate is a potent antiresorptive drug that has been extensively tested in patients with accelerated bone turnover."	2.68	A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone. ( Bitton, R; Bockman, RS; Bosco, BJ; Chausmer, A; Eyre, DR; Kotler, J; Levenson, D; Singer, F; Siris, E; Wilhelm, F, 1995)
"SAP and two markers of bone resorption, 24-hour urinary hydroxyproline/creatinine excretion (OHP) and 24-hour urinary calcium/creatinine excretion, were measured at baseline, 24 hours postinfusion (day 1) and on postinfusion days 3, 7, 10, and 14."	2.68	Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. ( Arden-Cordone, M; Knieriem, A; Lyles, KW; Newton, RA; Schaffer, V; Siris, ES; Zelenakas, K, 1997)
"An intravenous dosage schedule using pamidronate disodium, based on biochemical severity, was used to treat 71 patients with Paget's disease who had no previous bisphosphonate treatment."	2.68	Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study. ( Bhagat, CI; Gutteridge, DH; Kent, GN; Nicholson, GC; Price, RI; Prince, RL; Retallack, RW; Stewart, GO; Stuckey, BG; Thompson, RI; Ward, LC, 1996)
"Treatment with gallium nitrate (100 mg/m2 daily for 5 days, intravenously in 5% glucose) significantly reduced serum calcium, serum phosphate, urinary calcium, and the ratio of maximum tubular reabsorption of phosphate to glomerular filtration rate in each patient."	2.67	Use of gallium to treat Paget's disease of bone: a pilot study. ( Apseloff, G; Gerber, N; Matkovic, V; Shepard, DR, 1990)
" Four of the six patients in group 1A achieved normal ALP, whereas ALP remained at an increased level in all of the 10 patients in group 2 whose pretreatment ALP was greater than 1000 U/l, suggesting that a dose-response effect exists."	2.67	Clinical experience with pamidronate in the treatment of Paget's disease of bone. ( Boyce, BF; Boyle, IT; Gallacher, SJ; Jenkins, A; Patel, U; Ralston, SH, 1991)
"To assess the optimal dosage of oral tiludronate in Paget's disease of bone."	2.67	Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study. ( Colson, F; Combe, B; Ethgen, D; Geusens, P; Morlock, G; Reginster, JY, 1992)
"Pamidronate is a second generation bisphosphonate that has been used in Europe for the treatment of Paget's disease of bone for several years."	2.67	Effects of intravenous pamidronate therapy on Paget's disease of bone. ( Bombassei, GJ; Raisz, LG; Yocono, M, 1994)
"Paget's disease of bone is characterized by primary osteoclastic dysfunction and prolonged treatment with conventional medications including calcitonin and etidronate, results in a number of patients becoming refractory to treatment."	2.67	Pamidronate is effective for Paget's disease of bone refractory to conventional therapy. ( Gunasekera, RD; Wimalawansa, SJ, 1993)
" Fifty per cent of patients treated by a dose of 1200 mg/day reported gastrointestinal disturbances, however, making this dosage unsuitable for clinical practice."	2.67	Paget's disease of bone treated with a five day course of oral tiludronate. ( Deroisy, R; Ethgen, D; Franchimont, P; Lecart, MP; Reginster, JY; Zegels, B, 1993)
"Paget's disease of bone affects one or more bones and is characterized by increased bone turnover (remodelling) with hypertrophy and abnormal bone structure with diminished strength leading to deformity and fracture."	2.40	[Paget's disease of the bones: diagnosis and treatment]. ( Bijlsma, JW; Huisman, AM; Jacobs, JW; van Paassen, HC, 1999)
"Amongst the bone resorption markers studied are: 1) Calcium/creatinine urinary quotient; 2) Tartrate resistant acid phosphatase; 3) Urinary hydroxyproline; 4) Other substance derived from collagen disruption such as hydroxylysine glycoside, piridinolinic intermolecular bridges and the enzymatic activity of proline iminopeptidase."	2.38	[Usefulness of bone remodelling biochemical markers in the diagnosis and follow-up of Paget's bone disease, primary hyperparathyroidism, tumor hypercalcemia, and postmenopausal osteoporosis. II. Bone resorption markers]. ( de la Piedra Gordo, C; Torres Jiménez, R, 1990)
"Two of the patients had primary prostate cancer and one had a squamous cell lung tumour."	1.43	Inhibition of cancer cell mitosis by reducing the availability of phosphate. ( Condon, JR, 2016)
"Early-onset familial Paget disease of bone (EoPDB) is a rare condition caused by a 27-bp insertion mutation affecting the signal peptide of TNFRSF11A, which encodes RANK."	1.35	Clinical and biochemical response of TNFRSF11A-mediated early-onset familial Paget disease to bisphosphonate therapy. ( Imanishi, Y; Nakatsuka, K; Ralston, SH; Riches, PL, 2008)
"Oral pamidronate was added after 11 months of i."	1.32	Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy. ( Alvarez, V; Casco, C; Mautalen, C; Rubinstein, M; Tau, C, 2004)
"Treatment with etidronate disodium resulted in a temporary 40% reduction in serum alkaline phosphatase and 24 h urine hydroxyproline excretion, with reduction in serum osteocalcin from two times the upper limit of normal to a subnormal level."	1.29	Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate. ( Dempster, D; Lindsay, R; Parisien, M; Shane, E; Singer, F; Siris, E, 1994)
"The changes, however, in bone resorption and formation after bisphosphonate therapy are predictable, and their correct interpretation may allow a rational therapeutic approach applicable to the individual patient."	1.29	Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption. ( Frölich, M; Papapoulos, SE, 1996)
"All the urinary markers of bone resorption showed a prompt decline after bisphosphonates, with maximum reductions after 7-14 days: Pyr decreased by 43% +/- 9% and 42% +/- 22% (mean +/- SD), respectively in osteoporotic and pagetic subjects, OHP by 51% +/- 14% and 51% +/- 20%, and NTx by 55% +/- 15% and 65% +/- 26%."	1.29	Acute effects of bisphosphonates on new and traditional markers of bone resorption. ( Alfano, FS; Basini, G; Campanini, C; Fantuzzi, M; Gatti, C; Girasole, G; Passeri, M; Pedrazzoni, M, 1995)
"Paget's disease of bone is a localized progressive disease, characterized by increased bone remodeling, bone hypertrophy, and abnormal bone structure, leading to pain and deformity."	1.29	Therapeutic strategy in Paget's disease of bone. ( Meunier, PJ; Vignot, E, 1995)
"The rate and degree of suppression of bone resorption were monitored in 6 of the patients similarly treated with intravenous dimethyl-APD at a dose of 4 mg/day for 10 days, by daily measurements of the 24 h urinary excretion of Pyr, Dpyr and OHP."	1.29	Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone? ( Colwell, A; Eastell, R; Hamdy, NA; Papapoulos, SE; Russell, RG, 1993)
"A 12-year-old Japanese girl with polyostotic fibrous dysplasia and endocrine concomitants, was treated with elcatonin, a synthetic eel calcitonin analogue, 10 MRC unit/twice a week given by intramuscular injection."	1.27	Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive urinary hydroxyproline excretion in polyostotic fibrous dysplasia (McCune-Albright's syndrome). ( Harada, Y; Ishikawa, J; Ishitobi, K; Kishimoto, H; Maeyama, I; Morio, Y; Yamamoto, K, 1983)
"Paget's disease of bone in 51 patients was treated with ethane-1, hydroxy-1,1 diphosphonate (EHDP) for six months at a dosage of 5 mg/kg/day."	1.27	Treatment of Paget's disease of bone with ethane-1, hydroxy-1,1 diphosphonate (EHDP) at a low dosage (5 mg/kg/day). ( Alexandre, CM; Chapuy, MC; Edouard, C; Johnston, CC; Meunier, PJ; Vignon, E, 1983)
" It is concluded that PIP activity dosage in serum may provide with urinary hydroxyproline, further information for the study of collagen metabolism in osteoblastic bone diseases during treatment."	1.27	[Determination of serum proline iminopeptidase activity using a fluorescent substrate in patients with Paget's disease and prostatic bone metastases. Preliminary results]. ( Bouvier, M; Colson, F; Mathieu, M; Tebib, J; Vianey-Liaud, C, 1986)
"In most cases bone resorption became normal within a week of treatment, whereas the return to normal bone formation took 3-6 months; this difference produced a transient imbalance between resorption and formation."	1.26	Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). ( Bijvoet, OL; Frijlink, WB; Heynen, G; te Velde, J, 1979)
"Six patients with Paget disease of bone were treated with a 6-mo course of disodium-ethane-1-hydroxy-1, 1-diphosphate (EHDP) at a dosage of 5 mg/kg/day (one patient) or 20 mg/kg/day (five patients)."	1.26	An apparent 1,25-dihydroxyvitamin D-independent stimulation of intestinal calcium absorption in patients with Paget disease of bone during a short-term diphosphonate therapy. ( Norman, DA; Pak, CY; Zerwekh, JE, 1981)
"Colchicine, 0."	1.26	Colchicine in the treatment of Paget disease of bone: a new therapeutic approach. ( Askari, AD; Theodors, A; Wieland, RG, 1981)
"Obstructive hydrocephalus may result."	1.26	Paget's disease and the nervous system. ( Culebras, A; Feldman, RG; Schmidek, HH, 1979)
"Osteitis deformans is a bone disease of still unknown aetiology which shows characteristic symptoms in the maxillofacial region."	1.26	[Osteitis deformans]. ( Pape, K, 1978)
"Patient's with carcinoma metastases in bone and Pagent's disease of bone have different patterns of collagen metabolite excretion."	1.26	Urinary excretion of hydroxyproline, hydroxylysine and hydroxylysine glycosides by patients with Paget's disease of bone and carcinoma with metastases in bone. ( Kelleher, PC, 1979)
"Recurrence is usually not a generalized process occurring throughout the skeleton, but remains restricted to one or several lesions."	1.26	Scintigraphic aspects of the recurrence of treated Paget's disease of bone. ( Bijvoet, OL; Frijlink, WB; Pauwels, EK; Vellenga, CJ, 1981)
"Etidronate has been more efficient in reducing biological parameters, whereas calcitonin has produced a faster symptomatic response."	1.26	[Treatment of Paget's disease of bone: diphosphonates or calcitonin?]. ( Courvoisier, B; Davoine, GA; Jung, A, 1981)
" The medication is generally well tolerated and at the recommended dosage there is no evidence of increased fracture rate."	1.26	Use of etidronate (EHDP) in Paget's disease of bone. ( Johnston, CC; Khairi, MR; Meunier, PJ, 1980)
"1."	1.26	Serum proline imino-peptidase activity in normal adult subjects and in patients with Paget's disease of bone. ( Francis, MJ; Smith, R; Walton, RJ; Whiteley, J, 1976)
"Glucagon given by intravenous infusion at a dosage of 0."	1.25	Glucagon in the treatment of Paget's disease of bone. ( Condon, JR, 1971)

Timeframe	Studies, this research(%)	All Research%
pre-1990	264 (77.42)	18.7374
1990's	73 (21.41)	18.2507
2000's	2 (0.59)	29.6817
2010's	2 (0.59)	24.3611
2020's	0 (0.00)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Urine N-telopeptide, Serum Vit D, Parathormone and Calcium Levels in Hyperemesis Gravidarum[NCT02862496]		60 participants (Anticipated)	Observational [Patient Registry]	2016-06-30	Recruiting
A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420]	Phase 1	4 participants (Actual)	Interventional	2005-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
URINARY HYDROXYPROLINE EXCRETION AND GROWTH. Physiological reviews, 1964, Volume: 44 Topics: Aging; Blood Chemical Analysis; Chemical Phenomena; Chemistry; Collagen; Diet; Growth; Growth Hormon	1964
PAGET'S DISEASE OF BONE: CLINICAL AND METABOLIC OBSERVATIONS. Medicine, 1964, Volume: 43 Topics: Alkaline Phosphatase; Aspirin; Blood; Bone and Bones; Calcium; Citrates; Fluorides; Geriatrics; Hear	1964
[Development, chemistry, and clinical pharmacology of fully synthetic human calcitonin (author's transl)]. Wiener klinische Wochenschrift, 1982, Feb-05, Volume: 94, Issue:3 Topics: Alkaline Phosphatase; Calcitonin; Calcium; Humans; Hydroxyproline; Kidney; Osteitis Deformans; Osteo	1982
Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs, 1994, Volume: 47, Issue:6 Topics: Animals; Bone Neoplasms; Bone Resorption; Calcinosis; Clinical Trials as Topic; Clodronic Acid; Dose	1994
Biochemical markers of bone turnover in Paget's disease of bone. Bone, 1999, Volume: 24, Issue:5 Suppl Topics: Alkaline Phosphatase; Biomarkers; Bone and Bones; Humans; Hydroxyproline; Osteitis Deformans	1999
[Paget's disease of the bones: diagnosis and treatment]. Nederlands tijdschrift voor geneeskunde, 1999, Apr-03, Volume: 143, Issue:14 Topics: Adult; Aged; Alkaline Phosphatase; Arthralgia; Arthroplasty, Replacement; Calcium; Diphosphonates; F	1999
[Corticosteroids and collagen metabolism]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1975, Dec-22, Volume: 30, Issue:51 Topics: Adrenal Cortex Hormones; Adult; Age Factors; Child; Collagen; Collagen Diseases; Hodgkin Disease; Hu	1975
Paget's disease of bone. Clinical orthopaedics and related research, 1977, Issue:127 Topics: Bone and Bones; Calcitonin; Calcium; Collagen; Etidronic Acid; Humans; Hydroxylysine; Hydroxyproline	1977
Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP). Clinical orthopaedics and related research, 1977, Issue:127 Topics: Alkaline Phosphatase; Bone and Bones; Calcitonin; Calcium; Deafness; Etidronic Acid; Fractures, Bone	1977
[Indications for urinary hydroxyproline determination]. Deutsche medizinische Wochenschrift (1946), 1976, Sep-17, Volume: 101, Issue:38 Topics: Arthritis, Rheumatoid; Bone Neoplasms; Hodgkin Disease; Humans; Hydroxyproline; Neoplasm Metastasis;	1976
[Usefulness of bone remodelling biochemical markers in the diagnosis and follow-up of Paget's bone disease, primary hyperparathyroidism, tumor hypercalcemia, and postmenopausal osteoporosis. II. Bone resorption markers]. Anales de medicina interna (Madrid, Spain : 1984), 1990, Volume: 7, Issue:10 Topics: Acid Phosphatase; Adult; Biomarkers; Bone Resorption; Child; Female; Follow-Up Studies; Humans; Hydr	1990
Long-term follow-up observations on treatment in Paget's disease of bone. Clinical orthopaedics and related research, 1987, Issue:217 Topics: Alkaline Phosphatase; Bone and Bones; Calcitonin; Diphosphonates; Follow-Up Studies; Humans; Hydroxy	1987
Paget's disease: state of the art. Clinical therapeutics, 1987, Volume: 9, Issue:6 Topics: Alkaline Phosphatase; Calcitonin; Etidronic Acid; Humans; Hydroxyproline; Osteitis Deformans; Plicam	1987
[Biological and isotope explorations in Paget's disease of bone]. Rhumatologie, 1971, Volume: 23, Issue:4 Topics: Acid Phosphatase; Alkaline Phosphatase; Blood Glucose; Blood Sedimentation; Calcium; Calcium Isotope	1971
Calcitonin in the treatment of Paget's disease of bone. Annals of internal medicine, 1972, Volume: 76, Issue:4 Topics: Alkaline Phosphatase; Antibodies; Calcitonin; Humans; Hydroxyproline; Osteitis Deformans; Parathyroi	1972
Parathyroid hormone and thyrocalcitonin: their mode of action and regulation. Annals of the New York Academy of Sciences, 1971, Jul-06, Volume: 179 Topics: Adenoma; Adenylyl Cyclases; Adult; Animals; Biological Transport; Bone and Bones; Bone Resorption; C	1971
Paget's disease of bone: problems and management. The Orthopedic clinics of North America, 1972, Volume: 3, Issue:3 Topics: Adrenocorticotropic Hormone; Alkaline Phosphatase; Aspirin; Bone Regeneration; Bone Resorption; Calc	1972
[Problems concerning clinical application of calcitonin]. Nihon rinsho. Japanese journal of clinical medicine, 1972, Volume: 30, Issue:3 Topics: Adult; Aged; Alkaline Phosphatase; Calcitonin; Calcium; Child, Preschool; Female; Fibrous Dysplasia	1972
Treatment of Paget's disease with fluoride. Seminars in drug treatment, 1972,Summer, Volume: 2, Issue:1 Topics: Alkaline Phosphatase; Bone and Bones; Fluorides; Humans; Hydroxyproline; Osteitis Deformans	1972
Treatment of Paget's disease with a diphosphonate (sodium etidronate). Seminars in drug treatment, 1972,Summer, Volume: 2, Issue:1 Topics: Alkaline Phosphatase; Bone and Bones; Calcium; Ethanol; Humans; Hydroxyproline; Organophosphonates;	1972
Recent advances in the unerstanding and management of metabolic bone disease. Proceedings of the Royal Society of Medicine, 1970, Volume: 63, Issue:9 Topics: Bone Diseases; Calcitonin; Collagen; Homocystinuria; Humans; Hydroxyproline; Hyperparathyroidism; Me	1970
The clinical physiology of calcium homeostasis, parathyroid hormone, and calcitonin. II. California medicine, 1971, Volume: 114, Issue:4 Topics: Adenoma; Alkaline Phosphatase; Calcitonin; Calcium; Dihydrotachysterol; Diuretics; Ergocalciferols;	1971
Some aspects of metabolic bone disease related to rheumatology. Rheumatology and physical medicine, 1971, Volume: 11, Issue:4 Topics: Absorptiometry, Photon; Adult; Aged; Aging; Bone Diseases; Bone Resorption; Calcium; Child; Estrogen	1971

Article	Year
[Combined treatment of Paget's disease of bone with calcitonin and the diphosphonate EHDP]. Schweizerische medizinische Wochenschrift, 1981, Dec-05, Volume: 111, Issue:49 Topics: Adult; Aged; Alkaline Phosphatase; Calcitonin; Drug Therapy, Combination; Etidronic Acid; Hormones;	1981
The effects of intravenous alendronate in Paget's disease of bone. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1995, Volume: 10, Issue:7 Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Analysis of Variance; Calcium; Diphospho	1995
Comparison of methods of assessing response of Paget's disease to bisphosphonate therapy. Bone, 1995, Volume: 16, Issue:2 Topics: Alkaline Phosphatase; Bone and Bones; Bone Remodeling; Diphosphonates; Follow-Up Studies; Half-Life;	1995
Galactosyl hydroxylysine in assessment of Paget's bone disease. Clinica chimica acta; international journal of clinical chemistry, 1995, Jan-31, Volume: 234, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Resorption; C	1995
Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis and rheumatism, 1995, Volume: 38, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Diphosphonates; Dose-Response Relationship, Dr	1995
Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1995, Volume: 10, Issue:3 Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Biomarkers; Bon	1995
A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone. The Journal of clinical endocrinology and metabolism, 1995, Volume: 80, Issue:2 Topics: Adult; Aged; Alkaline Phosphatase; Bone Resorption; Creatinine; Dose-Response Relationship, Drug; Fe	1995
A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone. The Journal of rheumatology, 1994, Volume: 21, Issue:11 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Child; Creatinine; Diphosphonates; Female; Humans; Hy	1994
Effects of intravenous pamidronate therapy on Paget's disease of bone. The American journal of the medical sciences, 1994, Volume: 308, Issue:4 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Calcium; Diphosphonates; Female; Humans; Hydroxyproli	1994
Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile. Drugs under experimental and clinical research, 1994, Volume: 20, Issue:3 Topics: Aged; Alkaline Phosphatase; Body Temperature; Bone and Bones; Calcium; Diphosphonates; Ergocalcifero	1994
Treatment of patients with advanced Paget's disease of bone with two cycles of gallium nitrate. Seminars in arthritis and rheumatism, 1994, Volume: 23, Issue:4 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Dose-Response Relationship, Drug; Gallium; Humans; Hy	1994
Intravenous pamidronate: evolution of an effective treatment strategy. Seminars in arthritis and rheumatism, 1994, Volume: 23, Issue:4 Topics: Aged; Alkaline Phosphatase; Diphosphonates; Drug Administration Schedule; Humans; Hydroxyproline; In	1994
Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1994, Volume: 9, Issue:5 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Creatinine; Diphosphonates; Fem	1994
[The treatment of Paget's disease of bone with second-generation bisphosphonates via intravenous infusion]. Revista clinica espanola, 1993, Volume: 193, Issue:9 Topics: Aged; Alkaline Phosphatase; Diphosphonates; Female; Humans; Hydroxyproline; Infusions, Intravenous;	1993
Pamidronate is effective for Paget's disease of bone refractory to conventional therapy. Calcified tissue international, 1993, Volume: 53, Issue:4 Topics: Alkaline Phosphatase; Calcitonin; Creatinine; Diphosphonates; Drug Administration Schedule; Drug Res	1993
Paget's disease of bone treated with a five day course of oral tiludronate. Annals of the rheumatic diseases, 1993, Volume: 52, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Creatinine; Diphosphonates; Dos	1993
The methodology of clinical trials of oral tiludronate in Paget's disease of bone. Bone, 1995, Volume: 17, Issue:5 Suppl Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Development; Creatinine; Diphosphonates;	1995
Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study. Bone, 1996, Volume: 19, Issue:4 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Bone and Bones; Diphosphonates;	1996
Alendronate in the treatment of Paget's disease of bone. Bone, 1997, Volume: 20, Issue:3 Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Biopsy; Calcium; Female; Humans; Hydroxyproline	1997
Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcified tissue international, 1997, Volume: 60, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Resorption; Calcium; Creatini	1997
Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. Bone, 1999, Volume: 24, Issue:5 Suppl Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Resorption; Creatinine; Diphosphonates; Dose-Response R	1999
[Treatment of Paget's disease with salmon thyrocalcitonin. Cooperative double-blind study]. La Nouvelle presse medicale, 1976, Apr-23, Volume: 6, Issue:17 Topics: Adult; Aged; Alkaline Phosphatase; Animals; Calcitonin; Clinical Trials as Topic; Drug Evaluation; H	1976
Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet (London, England), 1979, Sep-08, Volume: 2, Issue:8141 Topics: Administration, Oral; Aged; Alkaline Phosphatase; Bone and Bones; Calcium; Clodronic Acid; Diphospho	1979
[Treatment of Paget's disease with salmon calcitonin]. Revue du rhumatisme et des maladies osteo-articulaires, 1977, Volume: 44, Issue:1 Topics: Aged; Alkaline Phosphatase; Bone Resorption; Calcitonin; Calcium; Clinical Trials as Topic; Female;	1977
A new diphosphonate: dissociation between effects on cells and mineral in rats and a preliminary trial in Paget's disease. Advances in experimental medicine and biology, 1978, Volume: 103 Topics: Animals; Bone and Bones; Bone Resorption; Calcium; Clinical Trials as Topic; Diphosphonates; Humans;	1978
Diphosphonate therapy of paget's disease of bone. The Journal of clinical endocrinology and metabolism, 1977, Volume: 44, Issue:1 Topics: Alkaline Phosphatase; Clinical Trials as Topic; Dose-Response Relationship, Drug; Etidronic Acid; Fe	1977
Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. Annals of internal medicine, 1977, Volume: 87, Issue:6 Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Matrix; Clinical Trials as Topic; Etidronic	1977
Combined diphosphonate and calcitonin therapy for Paget's disease of bone. Calcified tissue research, 1976, Volume: 21 Suppl Topics: Alkaline Phosphatase; Calcitonin; Clinical Trials as Topic; Drug Therapy, Combination; Etidronic Aci	1976
Short-term treatment of Paget's disease of bone with ipriflavone. Bone and mineral, 1992, Volume: 19 Suppl 1 Topics: Administration, Oral; Aged; Alkaline Phosphatase; Bone and Bones; Creatinine; Double-Blind Method; F	1992
Effects of five daily 1 h infusions of alendronate in Paget's disease of bone. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1992, Volume: 7, Issue:1 Topics: Aged; Alendronate; Alkaline Phosphatase; Calcium; Diphosphonates; Double-Blind Method; Drug Administ	1992
Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study. Arthritis and rheumatism, 1992, Volume: 35, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Creatinine; Diphosphonat	1992
Clinical experience with pamidronate in the treatment of Paget's disease of bone. Annals of the rheumatic diseases, 1991, Volume: 50, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Creatinine; Diphosphonates; Dose-Response Rela	1991
Treatment of Paget's disease of bone with a combination of intranasal salmon calcitonin and oral calcium and thiazide. Calcified tissue international, 1991, Volume: 49, Issue:3 Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphata	1991
Use of gallium to treat Paget's disease of bone: a pilot study. Lancet (London, England), 1990, Jan-13, Volume: 335, Issue:8681 Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents; Bone Regeneration; Bone Resorption; Clinical Tria	1990
Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clinical orthopaedics and related research, 1987, Issue:217 Topics: Administration, Oral; Alkaline Phosphatase; Biopsy; Bone and Bones; Clinical Trials as Topic; Clodro	1987
The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease--a double-blind randomized clinical study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1987, Volume: 2, Issue:1 Topics: Alkaline Phosphatase; Calcitriol; Creatinine; Double-Blind Method; Etidronic Acid; Humans; Hydroxypr	1987
Clinical experience with the use of two diphosphonates in the treatment of Paget's disease. Annals of the rheumatic diseases, 1985, Volume: 44, Issue:1 Topics: Aged; Alkaline Phosphatase; Clinical Trials as Topic; Creatinine; Diphosphonates; Etidronic Acid; Hu	1985
Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone. The American journal of medicine, 1985, Volume: 79, Issue:5 Topics: Aged; Alkaline Phosphatase; Clinical Trials as Topic; Drug Resistance; Etidronic Acid; Female; Follo	1985
Diphosphonates in Paget's disease. Lancet (London, England), 1974, May-11, Volume: 1, Issue:7863 Topics: Administration, Oral; Alkaline Phosphatase; Biopsy; Bone and Bones; Bone Resorption; Calcium; Clinic	1974
Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. Lancet (London, England), 1968, Apr-27, Volume: 1, Issue:7548 Topics: Adult; Aged; Calcitonin; Calcium; Creatinine; Female; Humans; Hydroxyproline; Hypercalcemia; Hyperth	1968
Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). The New England journal of medicine, 1973, Dec-27, Volume: 289, Issue:26 Topics: Administration, Oral; Aged; Alkaline Phosphatase; Bone and Bones; Clinical Trials as Topic; Dose-Res	1973
Treatment of Paget disease of bone (osteitis deformans). Results of a one-year study with sodium etidronate. JAMA, 1974, Oct-28, Volume: 230, Issue:4 Topics: Age Factors; Aged; Alkaline Phosphatase; Clinical Trials as Topic; Drug Evaluation; Etidronic Acid;	1974
Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia. The Journal of clinical endocrinology and metabolism, 1970, Volume: 31, Issue:3 Topics: Adolescent; Aged; Alkaline Phosphatase; Calcitonin; Calcium; Clinical Trials as Topic; Collagen; Cre	1970
The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone. The Journal of clinical investigation, 1971, Volume: 50, Issue:9 Topics: Aged; Alkaline Phosphatase; Animals; Audiometry; Bone and Bones; Bone Resorption; Calcitonin; Calciu	1971

hydroxyproline and Osteitis Deformans

Research Excerpts

Research

Studies (341)

Authors

Clinical Trials (2)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Maia, JM	1
Alves, R	1
Faria, R	1
Farinha, F	1
Condon, JR	3
Riches, PL	1
Imanishi, Y	1
Nakatsuka, K	2
Ralston, SH	3
HENNEMAN, PH	1
DULL, TA	1
AVIOLI, LV	7
BASTOMSKY, CH	1
LYNCH, TN	1
SMILEY, JD	1
ZIFF, M	1
DUBOVSKY, J	2
FORMANKOVA, J	3
DUBOVSKA, E	1
DE DEUXCHAISNES, CN	1
KRANE, SM	9
GOIDANICH, IF	1
LENZI, L	1
SILVA, E	1
CRABBE, P	1
ISSELBACHER, KJ	1
MCDONALD, JE	1
SINGER, RA	1
Tau, C	1
Mautalen, C	5
Casco, C	2
Alvarez, V	1
Rubinstein, M	1
Muñoz, AJ	2
Harris, ED	3
Borel, JP	3
Caranjot, JM	1
Jayle, MF	1
Galmiche, P	1
Lévy, P	1
Caniggia, A	3
Nuti, R	3
Vattimo, A	4
Galli, M	1
Turchetti, V	2
Franci, B	1
Martorelli, T	1
Righi, G	2
Douglas, DL	5
Duckworth, T	2
Russell, RG	17
Kanis, JA	17
Preston, CJ	7
Preston, FE	2
Prenton, MA	1
Woodhead, JS	2
Mathä, R	1
Kovarik, J	2
Woloszczuk, W	2
Plenk, H	1
Willvonseder, R	1
Böhler, N	1
Seidl, G	1
Höfer, R	1
Harris, ST	1
Neer, RM	2
Segre, GV	1
Petkau, AJ	1
Tully, GL	1
Daly, M	1
Potts, JT	3
Beard, DJ	5
Cameron, EC	2
Forrest, AR	1
Guilland-Cumming, D	1
Paterson, AD	2
Poser, J	1
Milford-Ward, A	1
Woodhead, S	1
Simon, LS	1
Wortman, PD	1
Krane, IM	1
Kovitz, KL	1
Chapuy, MC	11
Charhon, SA	1
Meunier, PJ	14
Renier, JC	3
Delmas, PD	4
Adami, S	4
Guarrera, G	2
Salvagno, G	2
Spiazzi, G	1
Marini, G	1
Rosini, S	3
Lo Cascio, V	3
Ziegler, R	6
Baldauf, G	1
Alexandre, CM	1
Vignon, E	5
Edouard, C	6
Johnston, CC	9
Yamamoto, K	1
Maeyama, I	1
Kishimoto, H	1
Morio, Y	1
Harada, Y	1
Ishitobi, K	1
Ishikawa, J	1
Mautalen, CA	2
Smith, ML	2
Fogelman, I	5
Ralston, S	1
Boyce, BF	3
Boyle, IT	3
Fraser, TR	2
Ibbertson, HK	3
Holdaway, IM	1
Rutland, M	1
King, A	1
Dodd, G	1
Wattie, DJ	2
Alexandre, C	5
Bressot, C	3
Trechsel, U	2
Mathieu, L	4
Preston, C	2
Smith, TW	1
Underwood, I	1
Bijvoet, OL	16
Frijlink, WB	4
Jie, K	1
van der Linden, H	1
Meijer, CJ	1
Mulder, H	2
van Paassen, HC	2
Reitsma, PH	2
te Velde, J	2
de Vries, E	1
van der Wey, JP	1
Surtees, J	1
Robinson, V	1
Arlot, ME	1
Charhon, S	2
Briancon, D	1
Reiner, JC	1
Bontoux-Carre, E	1
Seret, P	1
Villayleck, S	1
Gundberg, CM	1
Lian, JB	1
Gallop, PM	1
Steinberg, JJ	1
Khairi, MR	5
Siris, ES	3
Canfield, RE	2
Jacobs, TP	2
Baquiran, DC	1
Arlot, M	1
Norman, DA	1
Zerwekh, JE	1
Pak, CY	2
Davoine, GA	1
Jung, A	3
Courvoisier, B	4
Jaeger, P	4
Bischoff-Delaloye, A	1
Burckhardt, P	7
Heynen, G	2
Delwaide, P	1
Franchimont, P	8
Ghiringhelli, G	4
Fogel, M	1
Varela de Rodríguez, J	1
Mautelén, C	1
Nusimovich, B	1
Gilbertson, TJ	1
Brunden, MN	1
Gruszczyk, SB	1
Whyte, MP	1
Burnett, MA	1
Gerschpacher, H	1
Schindler, H	1
D'Amore, M	2
Quarto, S	1
Terlizzi, N	1
Martiradonna, A	1
Carrozzo, M	2
Hobitz, H	1
Evans, RA	2
Dunstan, CR	2
Wong, SY	1
Hills, E	2
Lender, M	1
Menczel, J	1
Bozzi, A	1
Telesca, ML	1
Vellenga, CJ	2
Pauwels, EK	1
Szymanowicz, A	3
Grunstein, HS	1
Clifton-Bligh, P	1
Posen, S	1
Kuhlencordt, F	2
Ringe, JD	2
Kruse, HP	2
Bower, L	1
Manley, G	1
Theodors, A	1
Askari, AD	1
Wieland, RG	1
O'Doherty, DP	2
McCloskey, EV	4
Vasikaran, S	2
Khan, S	1
Plosker, GL	1
Goa, KL	1
Smith, R	10
Blumsohn, A	2
Naylor, KE	1
Assiri, AM	2
Eastell, R	4
Pedrazzoni, M	1
Alfano, FS	1
Gatti, C	1
Fantuzzi, M	1
Girasole, G	1
Campanini, C	1
Basini, G	1
Passeri, M	3
Luboshitzky, R	1
Bar-Shalom, R	1
Patel, S	2
Coupland, CA	1
Stone, MD	3
Hosking, DJ	6
Michalsky, M	1
Stepan, JJ	1
Wilczek, H	1
Moro, L	2
Roux, C	2
Gennari, C	5
Farrerons, J	1
Devogelaer, JP	1
Picot, C	2
Titeux, L	1
Reginster, JY	9
Dougados, M	1
Alvarez, L	2
Guañabens, N	2
Peris, P	2
Monegal, A	2
Bedini, JL	1
Deulofeu, R	1
Martinez de Osaba, MJ	1
Muñoz-Gomez, J	1
Rivera-Fillat, F	1
Ballesta, AM	2
Bockman, RS	3
Wilhelm, F	1
Siris, E	4
Singer, F	3
Chausmer, A	1
Bitton, R	1
Kotler, J	1
Bosco, BJ	1
Eyre, DR	2
Levenson, D	1
Chakravarty, K	1
Merry, P	1
Scott, DG	1
Bombassei, GJ	1
Yocono, M	1
Raisz, LG	1
Vega, E	2
Roldán, EJ	1
Pérez Lloret, A	1
Kaddam, IM	1
Iqbal, SJ	1
Holland, S	1
Wong, M	1
Manning, D	1
Sharp, CA	1
Worsfold, M	1
Rowlands, PR	1
Davie, MW	1
Colwell, A	2
Hannon, RA	1
al-Dehaimi, AW	1
Peel, NF	1
Papapoulos, SE	6
Bosco, B	2
Anderson, DC	2
Richardson, PC	1
Brown, JK	1
Freemont, AJ	1
Hollis, S	1
Denton, J	1
Buckler, HM	1
Hargreaves, S	1
Cantrill, JA	1
Grauer, A	2
Klar, B	1
Scharla, SH	2
Zieglar, R	1
Fritz, P	1
Lioté, F	1
Kuntz, D	2
Stuckey, BG	3
Gutteridge, DH	4
Stewart, GO	3
Prince, RL	3
Ward, LC	2
Kent, GN	4
Prince, RI	1
Retallack, RW	4
Bhagat, CI	4
Nicholson, GC	3
Treves, R	1
Amor, B	1
Sany, J	1
Ethgen, D	3
Shane, E	1
Dempster, D	1
Lindsay, R	1
Parisien, M	1
Zamberlan, N	1
Mian, M	1
Dorizzi, R	1
Rossini, M	1
Braga, B	1
Gatti, D	1
Bertoldo, F	1
Locascio, V	1
Arboleya, L	1
Sánchez, J	1
Iglesias, G	1
Arranz, JL	1
Hamdy, NA	4
Wimalawansa, SJ	1
Gunasekera, RD	1
Coupland, C	1
Nunziata, V	1
Giannattasio, R	1
di Giovanni, G	1
Lettera, AM	1
Nunziata, CA	1
Lecart, MP	2
Deroisy, R	2
Zegels, B	1
Price, RI	3
Johnston, CA	1
Vignot, E	1
de la Piedra, C	5
Rapado, A	5
Díaz Diego, EM	1
Díaz Martín, MA	1
Aguirre, C	1
López Gavilanes, E	1
Díaz Curiel, M	2
Khan, SA	2
Orgee, J	2
Coombes, GM	1
Thompson, RI	2
Frölich, M	2
Benéton, MN	5
Rogers, S	1
Coulton, L	1
Coombes, G	1
Arden-Cordone, M	1
Lyles, KW	1
Knieriem, A	1
Newton, RA	1
Schaffer, V	1
Zelenakas, K	2
Rivero Marcotegui, A	1
Palacios Sarrasqueta, M	1
Grijalba Uche, A	1
Martínez Rodríguez, JL	1
Sorbet Zubiría, MJ	1
García Merlo, S	1
Singer, FR	10
Clemens, TL	1
Eusebio, RA	1
Bekker, PJ	1
Tarquini, R	1
Perfetto, F	1
Tarquini, B	1
Koga, K	1
Kawasaki, K	1
Kohno, S	1
Yamada, K	1
Itoh, T	1
Nonaka, K	1
Buckler, H	1
Fraser, W	1
Hosking, D	1
Ryan, W	1
Maricic, MJ	1
Davie, M	1
Birbara, CA	1
Moses, AM	1
Lyles, K	1
Selby, P	1
Richardson, P	1
Seaman, J	1
Jacobs, JW	1
Huisman, AM	1
Bijlsma, JW	1
Pons, F	1
Vidal-Sicart, S	1
Pavía, J	1
Muños-Gómez, J	1
Herranz, R	1
van Aken, J	1
Will, EJ	1
Bouvet, JP	1
Vignon, C	1
Stĕpán, J	2
Pacovský, V	1
Horn, V	1
Silinková-Málková, E	1
Vokrouhlická, O	1
Konopásek, B	1
Hrba, J	1
Marek, J	1
Baran, DT	1
Jaffe, BM	1
Ryckewaert, A	1
Lemaire, V	1
Tubiana, M	1
Eisinger, J	2
Laponche, AM	1
Roux, H	1
Recordier, AM	3
Ryan, WG	5
Theil, GB	1
Ajlouni, K	1
Scott, DJ	1
Cullen, JC	1
Henley, JW	2
Stephens, ES	1
Tait, B	1
Meunier, P	2
Terrier, M	1
David, L	1
Vignon, G	1
Grzywa, M	1
Rosenthall, L	1
Kaye, M	1
Feldman, RG	1
Culebras, A	1
Schmidek, HH	1
Pape, K	1
Croxson, RS	1
Avramides, A	6
Manderlier, T	1
Fuss, M	1
Brauman, J	1
Orloff, S	1
Bergans, A	1
Corvilain, J	1
Lemkes, HH	1
Frijlink, W	1
Verlinden-Ooms, H	1
Enderle, A	1
von Gumppenberg, S	1
Canfield, R	1
Rosner, W	1
Skinner, J	1
McWhorter, J	1
Resnick, L	1
Feldman, F	1
Kammerman, S	1
Ryan, K	1
Kunigonis, M	1
Bohne, W	1
Walton, RJ	4
Bartlett, M	1
Kantrowitz, FG	1
Byrne, M	1
Pinnell, SR	1
Woodhouse, NJ	8
Mohamedally, SM	3
Saed-Nejad, F	1
Martin, TJ	2
Rashid, M	1
Khairi, A	1
Johnston, C	1
Altman, RD	4
DeRosa, GP	1
Zimmermann, J	1
Schenk, RK	1
Malgras, A	2
Randoux, A	2
Kelleher, PC	1
Verch, RL	1
Wallach, S	7
Peabody, RA	1
Dakkak, R	1
Goussault, Y	1
Dreux, C	1
Sturtridge, WC	1
Harrison, JE	1
Wilson, DR	1
Chalmers, AH	1
Wells, IP	1
Dewbury, KC	1
Basu, TK	1
Smethurst, M	1
Gillett, MB	1
Donaldson, D	1
Jordan, SJ	1
Williams, DC	1
Hicklin, JA	1
Jesserer, H	2
Zita, G	2
Drexler, H	2
Wootton, R	2
Reeve, J	2
Spellacy, E	1
Tellez-Yudilevich, M	1
Deplante, JP	2
Daumont, A	1
Bouvier, M	3
Lejeune, E	2
Ambanelli, U	1
Ferraccioli, GF	1
Bernardi, P	1
Servemti, G	1
Holz, G	1
Minne, H	1
Delling, G	1
Williams, CP	1
Meachim, G	1
Taylor, WH	2
Veall, N	1
Burkhardt, H	1
Wepler, R	1
Rommel, K	1
de Vries, HR	2
Froeling, PG	1
Guideri, R	1
Nardi, P	1
Courpron, P	1
Bernard, J	1
Whiteley, J	1
Francis, MJ	2
Mermillod, B	1
Schenk, R	2
Burkhardt, P	1
Epiney, J	1
Fournié, A	3
Valverde, C	1
Tap, G	1
Bazerque, JJ	1
Ayrolles, C	1
Epstein, S	2
Owen, G	1
Oreopoulos, DG	1
Husdan, H	1
Harrison, J	1
Meema, HE	1
McNeill, KG	1
Murray, TM	1
Ogilvie, R	1
Rapoport, A	1
Woods, CG	3
Clark, MB	1
Horwith, M	1
Nunez, EA	1
Krook, L	1
Viteri, F	1
Torun, B	1
Mena, E	1
Suh, SM	1
Eisenberg, E	1
MacIntyre, I	7
Whalen, JP	1
Crosbie, WA	2
Meyer, RD	1
Flores, A	3
Bellavia, J	1
Cohn, S	1
Kalu, DN	3
Doury, P	1
Delahaye, RP	1
Leguay, G	1
Pattin, S	1
Metges, PJ	1
Montely, JM	1
Duret, JC	1
Salhi, A	1
Reiner, M	3
Seiler, A	1
Fleisch, H	2
Cosson, R	1
Daumont, R	1
Blotman, F	2
Blard, JM	1
Labauge, R	1
Simon, L	2
DeRose, J	3
Fabier, JL	1
Viau, M	1
Constans, J	1
Clerc, A	1
Roques, CF	1
Mazières, B	1
Amigues, H	1
Arlet, J	1
Ruffié, R	1
Ryan, PJ	2
Sherry, M	1
Gibson, T	2
Agnusdei, D	1
Camporeale, A	1
Gonnelli, S	1
Baroni, MC	2
Bettica, P	1
Robins, SP	2
Taylor, AK	1
Talbot, J	1
Baylink, DJ	1
Thiébaud, D	4
Portmann, L	1
Hanson, DA	1
Weis, MA	1
Bollen, AM	1
Maslan, SL	1
Gertz, BJ	1
Tindale, W	1
Sciberras, DG	1
Survill, TT	1
Colson, F	2
Morlock, G	1
Combe, B	1
Geusens, P	1
Jeugmans-Huynen, AM	2
Wouters, M	1
Sarlet, N	1
McIntyre, HD	1
Gallacher, SJ	1
Patel, U	1
Jenkins, A	2
Torres, R	3
Black, D	1
Paterson, CR	1
Reid, DM	1
Duncan, A	1
Seibel, MJ	1
Somers, NM	1
Evans, M	1
Matkovic, V	1
Apseloff, G	1
Shepard, DR	1
Gerber, N	1
Castro-Errecaborde, N	1
Alvarez-Arroyo, MV	1
Traba, ML	2
Fenton, AJ	1
Worth, GK	1
Watson, IG	1
Barry-Walsh, C	1
Hawthorne, AB	1
Kerr, D	1
Webster, G	1
de la Piedra Gordo, C	1
Torres Jiménez, R	1
Warrell, RP	1
Weinerman, S	1
Levine, B	1
Lane, J	1
Denis, D	2
Vandalem, JL	1
Collette, J	1
Muff, R	1
Dambacher, MA	2
Perrenoud, A	1
Simon, C	1
Fischer, JA	1
Beneton, M	1
Harris, S	1
Ravault, A	1
Miravet, L	1
Fournié, B	1
Lassoued, S	1
Igarashi, S	1
Jacquet, AF	2
Clemens, TP	1
McMahon, D	1
Gordon, A	1
Drake, S	1
Massie, JD	1
Postlethwaite, AE	1
Palmieri, GM	1
Salson, C	2
Palummeri, E	1
Quaini, F	1
Quintavalla, A	1
Barbagallo, M	1
Franchini, D	1
Ugolotti, D	1
Hoekman, K	1
Löwik, CW	1
Vermeij, P	2
Yates, AJ	3
Percival, RC	1
Gray, RE	5
Atkins, RM	2
Urwin, GH	3
Montesanti, F	1
Garavelli, S	1
Harinck, HI	4
Blanksma, HJ	3
Dahlinghaus-Nienhuys, PJ	1
Coulton, LA	1
Couch, M	1
Demiaux, B	1
Malaval, L	1
González, D	3
Murray, SA	1
Delmas, P	1
Wilder-Smith, CH	1
Raue, F	1
Holz-Gottswinter, G	1
Moolenaar, AJ	1
O'Donoghue, DJ	1
Cowan, RA	1
Albert, A	2
Gobelet, C	1
Frank, K	1
Climent, P	1
Mudde, AH	1
vd Berg, H	1
Tebib, J	1
Mathieu, M	1
Vianey-Liaud, C	1
Gambella, GR	1
Zunino, M	1
Würth, JP	1
Frielingsdorf, J	1
Hammel, T	1
Vetter, W	1
Guillard-Cumming, DF	1
Johnson, SK	1
Lawson-Matthew, PJ	1
Dewis, P	1
Prasad, BK	1
Willets, S	1
Niebauer, B	1
Frühwald, F	1
Kolbe, H	1
Gritten, C	1
Diverse, P	1
Hauwaert, PC	1
Crielaard, JM	1
Halleux, R	1
Morales Piga, A	1
García Vadillo, A	1
Rodríguez García, A	1
Elena Ibáñez, A	1
Castro Beiras, JM	1
Rodríguez Torrás, M	1
Crisp, AJ	1
Hazleman, BL	1
Minisola, S	1
Antonelli, R	1
Mazzuoli, G	1
Bishop, M	2
Bordier, P	1
Fisher, M	1
Joplin, GF	6
Foster, GV	1
Doyle, FH	4
Rojanasathit, S	1
Rosenberg, E	1
Haddad, JG	4
van der Sluys Veer, J	2
Jansen, AP	2
Wellman, H	1
Serafini, AN	2
Sankey, RR	2
Bishop, MC	1
Wellman, HN	2
Kaiser, G	1
Kyselka, R	1
Mühlbach, R	3
Hirthe, D	2
Beck, O	1
Schramm, G	1
Lindenhayn, K	2
Dell'Anno, R	1
Schwartz, TB	4
Northrop, G	2
Genuth, SM	1
Klein, L	1
Elias, EG	1
Evans, JT	1
Hamilton, CR	2
Quesada, O	1
Russell, AS	1
Lentle, BC	1
Goldfield, EB	2
Hodgkinson, A	1
Lechi, C	1
Bianchi, I	1
Cominacini, L	1
Galvanini, G	1
Christiansen, C	1
Tonnesen, KH	1
Nagant de Deuxchaisnes, C	1
Rombouts-Lindemans, C	1
Baker, RK	4
Morii, H	1
Riggs, BL	2
Jowsey, J	1
Vaisrub, S	2
Aldred, JP	1
Bloch, KJ	1
Braiker, BM	1
Prendergast, JJ	1
Kolb, FO	1
Schuhmacher, CA	1
Scurry, MT	1
Deiss, WP	1
Robb, JA	1
Regal, R	1
Rossi, M	1
Claustre, J	1
Boasson, M	1
Jallet, P	1
Bernat, M	1
Pennock, J	2
Greenberg, PB	2
Glen, AC	1
Guncaga, J	1
Lauffenburger, T	1
Lentner, C	1
Haas, HG	2
Olah, AJ	1
Eytan, S	1
Matz, S	1
Bornstein, B	1
Franck, WA	1
Bress, NM	1
Fisher, MT	1
Hillyard, CJ	1
Dziadiw, R	1
Eisman, JA	1
Xipell, JM	1
Sloman, JG	1
Jerums, G	1
Bell, NH	2
Avery, S	1
Kleeman, CR	1
Massry, SG	1
Coburn, JW	1
Shai, F	1
Cohen, RD	1
Couranz, S	1
Zender, R	2
Niejadlik, DC	1
Arnaud, CD	1
Goldsmith, RS	1
Taylor, WF	1
McCall, JT	1
Sessler, AD	1
Perlia, CP	2
Birge, SJ	1
Eisinger, JB	1
Moulard, JC	1
Galante, L	1
Cochran, M	1
Peacock, M	1
Sachs, G	1
Nordin, BE	1
Cerda, JJ	1
Toskes, PP	1
Shopa, NA	1
Wilkinson, JH	1
Thiébaud, M	1
Umek, H	1
Imhof, H	1
Czitober, H	2
Raab, W	1
Brémová, A	1
Katz, FH	1
Kappas, A	1
Berman, M	1
Colwell, JA	1
Saval, F	1
Del Greco, F	1
Casey, DE	1